Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
NCT ID: NCT02896920
Last Updated: 2020-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
165 participants
OBSERVATIONAL
2016-09-20
2019-04-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
NCT03894956
Hidradenitis Suppurativa Patient Experience With Humira Treatment
NCT04132388
Etanercept in Hidradenitis Suppurativa
NCT00329823
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04242498
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants receiving adalimumab/ Humira®
Participants with HS for whom a change in treatment to Humira® is made by the treating physician
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Need a change in ongoing therapy for any reason, but not limited to inadequate response, intolerance, sub-optimal compliance, or patient preference. Patient will be approached to participate in the study after a decision to change patient's therapy for Humira® is made by the treating physician.
* Has provided written informed consent (Patient Authorization) for participation in the study
Exclusion Criteria
* Was treated with Humira®, or any other biologic agents for HS prior to baseline visit
* Has any other active skin disease or condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of HS
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute for Skin Advancement /ID# 152448
Calgary, Alberta, Canada
Alberta DermaSurgery Centre /ID# 153834
Edmonton, Alberta, Canada
Jason Ronald Sneath Medical Co /ID# 152462
Brandon, Manitoba, Canada
Winnipeg Clinic, Manitoba, CA /ID# 153830
Winnipeg, Manitoba, Canada
Wiseman Dermatology Research /ID# 153835
Winnipeg, Manitoba, Canada
Dr. Irina Turchin PC Inc. /ID# 152464
Fredericton, New Brunswick, Canada
Karma Clinical Trials /ID# 152444
St. John's, Newfoundland and Labrador, Canada
NewLab Clinical Research Inc. /ID# 152438
St. John's, Newfoundland and Labrador, Canada
Dr. Brown-Maher PMC INC. /ID# 152407
St. John's, Newfoundland and Labrador, Canada
Eastern Canada Cutaneous Resea /ID# 153832
Halifax, Nova Scotia, Canada
SimcoMed Health Ltd /ID# 152445
Barrie, Ontario, Canada
Dr. Wei Jing Loo Medicine Prof /ID# 157923
London, Ontario, Canada
Lynderm Research Inc. /ID# 152436
Markham, Ontario, Canada
SKIN Centre for Dermatology /ID# 152457
Peterborough, Ontario, Canada
York Dermatology Center /ID# 152403
Richmond Hill, Ontario, Canada
Niakosari Medicine Professional Corporation /ID# 157851
Toronto, Ontario, Canada
K. Papp Clinical Research /ID# 152446
Waterloo, Ontario, Canada
Dr. Isabelle Delorme Inc. /ID# 152408
Drummondville, Quebec, Canada
Clinique D /ID# 152406
Laval, Quebec, Canada
Dre. Angelique Gagne-Henley /ID# 152611
Saint-Jérôme, Quebec, Canada
Dermatologie Sima Inc. /ID# 152443
Verdun, Quebec, Canada
Hopital St-Sacrement /ID# 152456
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
clinical study report synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P15-696
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.